Season 8 · Episode 9
S8 Ep9: Rugo Summarizes Developments With Ribociclib and ADCs in HR-Positive Breast Cancer
OncLive® On Air · OncLive® On Air
December 26, 202215m 25s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr Rugo discusses the second interim analysis of overall survival in the TROPiCS-02 trial, the implications of post-progression treatments after ribociclib and endocrine therapy in the phase 3 MONALEESA-2, MONALEESA-3, and MONALEESA-7 studies, and what the AMALEE trial indicates about optimal starting doses of first-line ribociclib in hormone receptor–positive breast cancer.